SCHEMBL3550805

SCHEMBL3550805

CN1CC[C@@H](N)[C@@H]1Cc1ccccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.43
KCNH2 Q12809 1/20 0.41
ALDH1A1 P00352 1/20 0.40
ATM Q13315 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
CARM1 Q86X55 1/20 0.39
PRMT6 Q96LA8 1/20 0.39
TAAR1 Q96RJ0 1/20 0.38
AOC3 Q16853 1/20 0.38
PNMT P11086 1/20 0.38
CES2 O00748 1/20 0.37
LMNA P02545 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HTT P42858 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP2A13 Q16696 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5146706 1.00 CXCR4 (0.43) CXCR4KCNH2ALDH1A1ATMMAPT
SCHEMBL3551226 0.78 PRMT6 (0.45) KCNH2CARM1PRMT6SIGMAR1
SCHEMBL3550203 0.75 ALDH1A1 (0.41) KCNH2ALDH1A1
SCHEMBL3548356 0.74 HSD17B2 (0.47) ALDH1A1ATMMAPTCARM1PRMT6
SCHEMBL13344515 0.73 TSHR (0.48) ALDH1A1MAPTTSHRLMNAMEN1
SCHEMBL11375404 0.72 HTR6 (0.56)
SCHEMBL4278444 0.71 ALDH1A1 (0.55) CXCR4KCNH2ALDH1A1ATMMAPT
SCHEMBL3548008 0.71 ACHE (0.47) SIGMAR1KMT2A
SCHEMBL11469642 0.70 HTR6 (0.50) CXCR4ALDH1A1ATMMAPTKDM4E
SCHEMBL2086898 0.70 PNMT (0.48) CXCR4KCNH2ALDH1A1ATMTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7714021-B2 Pyrrolidin-3-yl compounds useful as beta-secretase inhibitors for the treatment of Alzheimer's disease MERCK & CO., INC. (US) 2010-05-11 US disclosed
US-20080287523-A1 Pyrrolidin-3-Yl Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease MERCK SHARP & DOHME LLC 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287523-A1 Pyrrolidin-3-Yl Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease BACE1, BACE2, APP CXCR4 3865/4885KCNH2 4219/4885ALDH1A1 2813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.